These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 26459098)
1. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer. Alsubhi N; Middleton F; Abdel-Fatah TM; Stephens P; Doherty R; Arora A; Moseley PM; Chan SY; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Martin SG; Curtin NJ; Madhusudan S Mol Oncol; 2016 Feb; 10(2):213-23. PubMed ID: 26459098 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy. Massey AJ Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461 [TBL] [Abstract][Full Text] [Related]
3. Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response. Al-Kaabi MM; Alshareeda AT; Jerjees DA; Muftah AA; Green AR; Alsubhi NH; Nolan CC; Chan S; Cornford E; Madhusudan S; Ellis IO; Rakha EA Br J Cancer; 2015 Mar; 112(5):901-11. PubMed ID: 25688741 [TBL] [Abstract][Full Text] [Related]
4. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089 [TBL] [Abstract][Full Text] [Related]
5. Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction. Xiao G; Kue P; Bhosle R; Bargonetti J Cell Cycle; 2015; 14(5):744-54. PubMed ID: 25565400 [TBL] [Abstract][Full Text] [Related]
6. The ATM and Rad3-Related (ATR) Protein Kinase Pathway Is Activated by Herpes Simplex Virus 1 and Required for Efficient Viral Replication. Edwards TG; Bloom DC; Fisher C J Virol; 2018 Mar; 92(6):. PubMed ID: 29263259 [TBL] [Abstract][Full Text] [Related]
7. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage. Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079 [TBL] [Abstract][Full Text] [Related]
8. Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3. Lian X; Bao C; Li X; Zhang X; Chen H; Jung YS; Qian Y J Virol; 2019 May; 93(9):. PubMed ID: 30787154 [TBL] [Abstract][Full Text] [Related]
9. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. Bryant C; Rawlinson R; Massey AJ BMC Cancer; 2014 Aug; 14():570. PubMed ID: 25104095 [TBL] [Abstract][Full Text] [Related]
10. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage. Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061 [TBL] [Abstract][Full Text] [Related]
11. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation. Gomes LR; Rocha CRR; Martins DJ; Fiore APZP; Kinker GS; Bruni-Cardoso A; Menck CFM Cell Death Dis; 2019 Jun; 10(6):459. PubMed ID: 31189884 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase. Wayne J; Brooks T; Massey AJ Oncotarget; 2016 Dec; 7(51):85033-85048. PubMed ID: 27829224 [TBL] [Abstract][Full Text] [Related]
13. Aurora-A controls cancer cell radio- and chemoresistance via ATM/Chk2-mediated DNA repair networks. Sun H; Wang Y; Wang Z; Meng J; Qi Z; Yang G Biochim Biophys Acta; 2014 May; 1843(5):934-44. PubMed ID: 24480460 [TBL] [Abstract][Full Text] [Related]
15. Hyperoxia activates the ATR-Chk1 pathway and phosphorylates p53 at multiple sites. Das KC; Dashnamoorthy R Am J Physiol Lung Cell Mol Physiol; 2004 Jan; 286(1):L87-97. PubMed ID: 12959929 [TBL] [Abstract][Full Text] [Related]
16. Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers? Abdel-Fatah TM; Perry C; Arora A; Thompson N; Doherty R; Moseley PM; Green AR; Chan SY; Ellis IO; Madhusudan S Antioxid Redox Signal; 2014 Dec; 21(16):2262-8. PubMed ID: 25111287 [TBL] [Abstract][Full Text] [Related]
17. Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts. Abdel-Fatah TM; Arora A; Alsubhi N; Agarwal D; Moseley PM; Perry C; Doherty R; Chan SY; Green AR; Rakha E; Ball G; Ellis IO; Madhusudan S Neoplasia; 2014 Nov; 16(11):982-91. PubMed ID: 25425972 [TBL] [Abstract][Full Text] [Related]
18. Radio-sensitizing effects of VE-821 and beyond: Distinct phosphoproteomic and metabolomic changes after ATR inhibition in irradiated MOLT-4 cells. Šalovská B; Janečková H; Fabrik I; Karlíková R; Čecháková L; Ondrej M; Link M; Friedecký D; Tichý A PLoS One; 2018; 13(7):e0199349. PubMed ID: 30001349 [TBL] [Abstract][Full Text] [Related]
19. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional. Lossaint G; Besnard E; Fisher D; Piette J; Dulić V Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626 [TBL] [Abstract][Full Text] [Related]
20. IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin. O'Flanagan CH; O'Shea S; Lyons A; Fogarty FM; McCabe N; Kennedy RD; O'Connor R Oncotarget; 2016 Aug; 7(35):56826-56841. PubMed ID: 27472395 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]